Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Jazz_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:CEO |
gptkb:Justin_Gover
|
| gptkbp:countryOfOrigin |
gptkb:United_Kingdom
|
| gptkbp:focusesOn |
cannabinoid-based medicines
|
| gptkbp:foundedBy |
gptkb:Brian_Whittle
gptkb:Geoffrey_Guy |
| gptkbp:foundedYear |
1998
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
GW Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Epidiolex
gptkb:Sativex |
| gptkbp:parentCompany |
gptkb:Jazz_Pharmaceuticals
|
| gptkbp:regulates |
EMA approval for Sativex
FDA approval for Epidiolex |
| gptkbp:researchInterest |
epilepsy
multiple sclerosis cancer pain |
| gptkbp:specializesIn |
cannabis-derived medicines
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:GWPH
|
| gptkbp:therapeuticArea |
neurology
oncology psychiatry |
| gptkbp:website |
https://www.gwpharm.com/
|
| gptkbp:bfsParent |
gptkb:GW
|
| gptkbp:bfsLayer |
5
|